Introduction
Transthyretin amyloidosis (ATTR amyloidosis) is a life-threatening disorder caused by the deposition of amyloid fibrils composed of misfolded monomers of the transport protein transthyretin (TTR) (Ando et al., 2013; Plante-Bordeneuve, 2014) . Extracellular deposits of amyloid transthyretin fibrils give rise to hereditary ATTR (ATTRm) amyloidosis when resulting from mutations in the TTR gene, and wild-type ATTR (ATTRwt) amyloidosis when non-mutated protein is deposited . These amyloid deposits progressively interfere with normal cell and organ functions and give rise to the variety of symptoms associated with ATTR amyloidosis (Ando et al., 2013; Plante-Bordeneuve, 2014) .
ATTR amyloidosis is often underdiagnosed, or in many cases the diagnosis is delayed for years relative to the symptom onset (Plante-Bordeneuve and Said, 2011; Coelho et al., 2013) . The clinical presentation of the disease is heterogeneous with multi-organ involvement, and individual patients tend to exhibit symptoms of progressive neuropathy or restrictive cardiomyopathy. The major causes of morbidity and mortality in patients with ATTR amyloidosis are cardiomyopathy and autonomic neuropathy, which can lead to death within approximately 3-5 or 10 years of disease onset, respectively Plante-Bordeneuve and Said, 2011; Castano et al., 2015; Connors et al., 2016) . Symptoms of autonomic neuropathy, such as gastrointestinal problems, loss of bladder control, or sexual impotence in men, often occur in the early stages of ATTR amyloidosis and tend to precede motor impairment (Gonzalez-Duarte, 2019; Benson and Kincaid, 2007) . Autonomic dysfunction requires investigations that may not be readily available in many clinical centers, but blood pressure (BP) monitoring is available in most settings, and observable changes in BP could be predictive of the need for more complex autonomic dysfunction testing. One measure associated with autonomic dysfunction that can easily be detected from BP measurements is orthostatic hypotension (OH) (Mathias, 2007) . The clinical signs and symptoms of OH can include light-headedness, dizziness, blurred vision, confusion, or fainting after standing up (Plante-Bordeneuve, 2014; Mathias, 2007) . OH has been commonly reported as a symptom of ATTR amyloidosis (Gertz et al., 1992; Rapezzi et al., 2013; Maurer et al., 2016) . Monitoring of OH may be a useful measure to detect early disease or to monitor disease progression.
The Transthyretin Amyloidosis Outcomes Survey (THAOS), established in 2007, is the largest ongoing observational and noninterventional registry of patients with ATTR amyloidosis Plante-Bordeneuve et al., 2013) . THAOS collects multinational longitudinal data on the natural history of the disease from a large and diverse patient population, and helps to inform the characterization of ATTR amyloidosis and improve diagnosis and patient management Plante-Bordeneuve et al., 2013) .
The aim of this study was to identify clinically meaningful variations in subsequent BP measurements that may be indicative of the symptoms of disease onset or progression. Using data from THAOS, we assessed the associations between the presence or absence of OH at enrollment, together with changes in BP and orthostatic difference over time, and clinical characteristics and disease progression.
Methods

Data collection
THAOS is a multinational longitudinal observational registry (ClinicalTrials.gov: NCT00628745), in which symptomatic subjects with ATTR amyloidosis, together with asymptomatic subjects with a confirmed TTR mutation, are eligible to be enrolled (Plante-Bordeneuve et al., 2013) . All participating study sites were approved by their local ethical or institutional review board prior to subject enrollment. Written informed consent was signed by all eligible subjects. Subjects' data were submitted electronically and remained confidential according to the country-specific regulations and guidelines. The study was carried out in accordance with the Declaration of Helsinki.
Demographic and clinical characteristics, TTR genotype, family history, and medical history were recorded at enrollment. Thereafter, subjects' neurological, cardiac, gastrointestinal, ophthalmic, and renal functions were regularly assessed. The design and methodology of THAOS have previously been described in detail (Plante-Bordeneuve et al., 2013).
Study population
All subjects in THAOS, including all subjects with ATTRwt and all symptomatic and asymptomatic subjects with ATTRm, were included in the analysis (analysis cut-off date: January 30, 2017). In addition, those subjects with OH recorded at enrollment were assessed separately and were divided into those with OH present and those with OH absent at enrollment.
End points and measures
OH is commonly defined as a drop of 20 mmHg or more in systolic BP (SBP) or 10 mmHg or more in diastolic BP (DBP) when standing up after sitting or lying down (supine) (Maurer et al., 2016; Davis et al., 1987; Freeman et al., 2011) . In this analysis, SBP and DBP, both sitting/ supine and after 3 min of standing, and orthostatic difference were assessed at enrollment, with results each year up to 3 years after enrollment included in the analysis.
Systolic and diastolic orthostatic differences were analyzed in all subjects with recorded BP measurements. Systolic orthostatic difference was calculated as the mean of the differences between standing and sitting SBP (SBP after 3 min of standing minus sitting SBP) for each subject. Diastolic orthostatic difference was calculated as the mean of the differences between standing and sitting DBP (DBP after 3 min of standing minus sitting DBP) for each subject.
Quality of life (QoL) was quantified using Norfolk Quality of Life Questionnaire-Diabetic Neuropathy Total Quality of Life (TQoL) score (range -4 to 136, with higher scores indicating poorer QoL) (Vinik et al., 2014) . In addition to the total score, the items of this self-administered questionnaire were grouped into 5 categories: physical functioning (large fiber score), small fiber, activities of daily living, symptoms, and autonomic scores, with higher scores indicating worse QoL. EuroQoL Five Dimensions (EQ-5D) is a standardized measure of health and was also used to assess QoL. EQ-5D includes a descriptive EQ-5D Index (range 0-1, with 1 indicating full health) and a visual analog scale (EQ-5D Health State; VAS; full health equals 100), with higher scores indicating better health status. Data on diarrhea, unintentional weight loss, and modified Polyneuropathy Disability (mPND) score were also included in the analysis. The mPND score evaluates walking capacity according to the following criteria: 0 -symptomatic, but no lower limb sensory/motor deficit; I -sensory disturbances in feet, but able to walk without difficulty; II -some difficulties walking, but can walk without aid; IIIa -able to walk with 1 cane or crutch; IIIbable to walk with 2 canes or crutches; IV -confined to wheelchair or bedridden.
Statistical analyses
Multiple regression analyses were carried out to identify potential predictors of sitting and standing SBP and DBP at enrollment. Age at enrollment, gender, genotype, symptomatic or asymptomatic, mPND score, presence or absence of diarrhea, and presence or absence of unintentional weight loss at enrollment were included in the regression model as independent variables. Multiple regression analyses were also carried out to identify potential predictors of change in sitting and standing BP and orthostatic difference from enrollment to Year 3. BP at enrollment, age at enrollment, gender, genotype, symptomatic or asymptomatic, mPND score at Year 3, presence or absence of diarrhea at Year 3, presence or absence of unintentional weight loss at Year 3, TQoL at Year 3, and EQ-5D Index score at Year 3 were included in the regression model as independent variables. In addition, BP at enrollment and orthostatic difference at enrollment were included in the analysis of change in sitting and standing BP and orthostatic difference at Year 3, respectively. Age, BP, orthostatic difference, TQoL, and EQ-5D Index score were treated as continuous variables, whereas gender (male or female), TTR genotype (mutated or wild-type TTR), symptomatic or asymptomatic, mPND score, diarrhea (presence or absence), and unintentional weight loss (presence or absence) were categorical variables.
Results
Demographic and clinical characteristics
A total of 3231 subjects (1834 men [56.8%] and 1397 women [43.2%]) were included in the analysis, 1896 (58.7%) of whom were symptomatic (subjects with definite symptoms linked to ATTR amyloidosis). The majority of subjects had ATTRm (2850 [88.2%]), and the rest had ATTRwt (381 [11.8%]). Mean (SD) age at enrollment was 50.2 (18.1) years, with the mean age of men being 8.7 years older than that of women. Mean (SD) age at symptom onset was 49.9 (17.6) years, and subjects had a mean duration of symptoms of 5.4 (5.5) years at enrollment.
Comparison of subjects with or without OH at enrollment
Of those subjects with the presence or absence of OH recorded at baseline (n = 2083), 243 (11.7%) presented with OH and 1840 (88.3%) without OH. Subjects with OH at enrollment were older, more likely to be male, and symptomatic compared with those without OH (Table 1) .
Notably, OH was more common (11.7%) than either diarrhea (2.4%) or unintentional weight loss (3.1%) in subjects who had OH status recorded at enrollment. The majority of subjects with OH at enrollment presented with more advanced functional deterioration in the lower limbs as measured by mPND score (Fig. 1 ). Nevertheless, OH as a symptom tended to be present relatively early in the course of disease progression (mPND stages 0, I, and II), before patients' ability to walk deteriorated further ( Fig. 1 ). Diarrhea and unintentional weight loss were reported marginally more frequently by subjects with OH at enrollment (Table 1) .
Subjects with OH at enrollment tended to have significantly higher TQoL scores (indicating worse QoL) than those without OH at enrollment (Table 2) . Similarly, subjects with OH at enrollment had significantly higher scores in all TQoL item categories ( Table 2 ). The EQ-5D Index and EQ-5D Health State scores were significantly lower (indicating worse health status) in subjects with OH present at enrollment (Table 2) .
At enrollment and at Years 1, 2, and 3 after enrollment, both systolic and diastolic orthostatic differences were greater in subjects with OH than in those without OH at enrollment (Table 3) .
The change from enrollment in systolic orthostatic difference increased progressively over time in subjects with OH at enrollment, whereas there was no change in systolic orthostatic difference in subjects without OH at enrollment ( Fig. 2a) . Similarly, diastolic orthostatic difference increased over time in subjects with OH, but not in those without OH, at enrollment ( Fig. 2b) .
BP and orthostatic difference at enrollment and up to 3 years from enrollment
In all subjects, sitting and standing SBP and DBP were recorded at enrollment (mean mmHg: sitting SBP 122.8; standing SBP 120.4; sitting DBP 75.5; standing DBP 78.8) and each year for up to 3 years. ATTRm, hereditary ATTR; ATTRwt, wild-type ATTR; OH, orthostatic hypotension. a Including 2083 subjects with OH recorded at enrollment. . 1 . mPND score of subjects with and without OH at enrollment.* mPND score: 0 -symptomatic, but no lower limb sensory/motor deficit; I -sensory disturbances in feet, but able to walk without difficulty; II -some difficulties walking, but can walk without aid; IIIa -able to walk with 1 cane or crutch; IIIb -able to walk with 2 canes or crutches; IV -confined to wheelchair or bedridden. *Including 2083 subjects with OH recorded at enrollment. 
Fig
Variables associated with BP and orthostatic difference at enrollment
Greater diastolic orthostatic difference at enrollment was significantly associated with older age (parameter estimate [SE], p value: 0.05 [0.022], 0.0308), higher mPND stage (1.10 [0.371], 0.0030), presence of diarrhea (3.56 [0.944], 0.0002), and unintentional weight loss (2.30 [0.861], 0.0077) (all at enrollment), whereas systolic orthostatic difference was not significantly associated with any of the assessed variables.
Variables associated with change in BP and orthostatic difference from enrollment to Year 3
Reduction in sitting SBP was significantly associated with lower sitting SBP and older age, both at enrollment (Table 4 ). Reduction in standing SBP was significantly associated with lower standing SBP and older age, both at enrollment, and increase in mPND stage at Year 3 (Table 4 ). Reduction in sitting DBP was significantly associated with lower sitting DBP at enrollment, presence of diarrhea, and higher EQ-5D Index score, both at Year 3 (Table 4 ). Reduction in standing DBP was significantly associated with lower standing DBP at enrollment (Table 4) .
Greater increase in systolic or diastolic orthostatic difference was significantly associated with smaller systolic or diastolic orthostatic difference at enrollment, the presence of diarrhea at Year 3, lower TQoL, and higher EQ-5D, both at Year 3 (Table 5 ). Greater increase in diastolic orthostatic difference was also significantly associated with higher mPND stage at Year 3 (Table 5) .
Discussion
Orthostatic hypotension is a sign of autonomic dysfunction in patients with ATTR amyloidosis (Ando et al., 2013 ) that can easily be diagnosed using sitting and standing BP measurements. In patients with polyneuropathy, symptoms of autonomic dysfunction occur frequently with early-onset disease (symptom onset at < 50 years of age) but are less common in those with late-onset disease (symptom onset at ≥50 years of age) (Plante-Bordeneuve and Said, 2011), occurring at least not until the later stages of the disease (Koike et al., 2002) . In this analysis, subjects with OH at enrollment were older, more likely to be symptomatic, and had higher mPND score and worse QoL than those without OH at enrollment. This, combined with the fact that systolic and diastolic orthostatic differences increased over time in subjects with OH at enrollment but not in subjects without OH at enrollment, is indicative of a faster progression of autonomic dysfunction in subjects with OH. As such, OH may be a useful parameter to monitor disease progression.
These results are in accordance with earlier studies in which OH was reported as a common symptom in subjects with more severe ATTR amyloidosis (Gertz et al., 1992; Rapezzi et al., 2013; Koike et al., 2002) . However, in this analysis, it is worth noting that OH was more common at enrollment than either diarrhea or unintentional weight loss, which are considered common early symptoms of autonomic dysfunction in ATTR amyloidosis (Ando et al., 2013; Plante-Bordeneuve and Said, 2011) . Analyzed subjects with OH tended to be at a more advanced disease stage than subjects without OH and it is possible that, for some patients, the presence of OH was the symptom that lead to diagnosis and enrollment in THAOS. Nevertheless, OH was present relatively early in the course of the disease (predominantly mPND stages 0, I, and II). In addition, nearly a third of subjects without OH were asymptomatic, while over 90% of those with OH were symptomatic. This suggests that OH could be utilized in conjunction with other signs and symptoms as an early diagnostic tool in a wide group of patients, as it may occur before other symptoms, such as diarrhea, are present.
Recent studies have focused on "inter visit" variations in BP, however, it is not clear to what extent these variations are clinically significant. When treating hypertension, BP variations, defined as the difference between BP measured at various visits, have been identified as predictors of stroke, coronary events and heart failure (Clement, 2011) . In this analysis we observed a trend towards lower SBP and DBP from enrollment to Year 3, in addition to an increase in the orthostatic differences. Larger reductions in BP and increased orthostatic differences were associated with a higher degree of neuropathy, reflected by a higher mPND score. This suggests that inter visit BP variability may reflect changes in disease progression in ATTR amyloidosis.
Data collection from observational surveys has several limitations. Consequences of gathering data from multiple centers and countries include the possibility of variations in the assessments, reduced completeness of data over time, and variations in the rigor with which the data are acquired. An important weakness of this study lies in the fact that the methods used to assess orthostatic differences varied between the examiners. Although some guidelines have suggested that sitting and supine BP readings can be considered equivalent (Sala et al., 2005) , clinical observations have provided evidence that SBP and DBP are higher in the supine than in the sitting position (Eser et al., 2007; Beevers et al., 2001; Netea et al., 1998) ; thus, there is a possibility that more patients met the criteria for OH than were identified in this analysis in which sitting BP was measured. At the same time, it was not clear whether heart rate was measured simultaneously or after the BP measurement and it was thus excluded from the analysis. Without heart rate measures to confirm otherwise, it may have been that some instances of OH could have been related to decreased blood volume as a A. González-Duarte, et al. Autonomic Neuroscience: Basic and Clinical 222 (2019) 102590 consequence of dehydration, although diarrhea (and unintentional weight loss) were present in only~6% of patients with OH. There are a number of other confounding variables that can influence orthostatic changes, including diurnal variability, age, medications, hydration, and food intake, and care should be taken to ensure consistent measurement of OH (Freeman et al., 2011) . Nevertheless, BP measurement and assessment of OH are largely objective measures that are less likely to vary to a meaningful degree between different centers than more complex or subjective assessments. One should also be careful in the interpretation of the cause-to-effect correlation; for example, the amplitude of variation could be largely due to increased episodes of diarrhea rather than solely due to increased neurogenic failure. While variation in BP might arise from the hydration status of an individual-which might be difficult to control in patients with ATTR amyloidosis, especially those in the later stages of the disease-the impact of this potential variability is likely limited by the large number of subjects in this analysis. Additionally, correlation to increased mPND score suggests that visit-to-visit blood BP variability may be a surrogate for homeostasis disruption and not solely caused by volume changes.
What is the clinical significance of these findings? We suggest that the clinician treating patients with ATTR amyloidosis integrates a standardized method for recording BP repeatedly in the same fashion at every visit, and that as many BP values as possible are recorded to allow for the determination of the variations over time. With data collected in this manner, the trend towards lower BP measurement can be analyzed as a possible marker of the disease progression over time when compared to earlier visits.
Of paramount importance, this study showed that OH was present more frequently than other common early symptoms associated with autonomic dysfunction in ATTR amyloidosis, and hence it could be a useful sign in early diagnosis. Visit-to-visit BP measurements, when carefully assessed and analyzed, can be used in real-world medical practice and evaluating changes in BP-related parameters over time might help to improve knowledge of the clinical course of ATTR amyloidosis and may translate to new therapeutic targets. 
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